Nukkleus Inc. (NASDAQ:DFNS – Get Free Report) was the target of a significant growth in short interest in August. As of August 31st, there was short interest totaling 301,468 shares, a growth of 108.6% from the August 15th total of 144,490 shares. Based on an average daily trading volume, of 1,811,869 shares, the days-to-cover ratio is currently 0.2 days. Currently, 20.4% of the shares of the stock are short sold.
Nukkleus Stock Performance
DFNS stock traded down $0.95 during midday trading on Tuesday, hitting $8.28. The stock had a trading volume of 410,792 shares, compared to its average volume of 1,320,614. The firm has a market capitalization of $13.78 million, a price-to-earnings ratio of -0.02 and a beta of -5.88. The company has a current ratio of 0.14, a quick ratio of 0.11 and a debt-to-equity ratio of 0.07. The stock has a 50-day simple moving average of $20.84 and a 200 day simple moving average of $59.31. Nukkleus has a 52 week low of $3.70 and a 52 week high of $1,948.75.
Nukkleus (NASDAQ:DFNS – Get Free Report) last announced its quarterly earnings data on Wednesday, August 19th. The company reported ($173.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.11) by ($170.69). The firm had revenue of $4.00 million for the quarter, compared to the consensus estimate of $4.50 million. As a group, equities research analysts anticipate that Nukkleus will post -3.9 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Get Our Latest Research Report on Nukkleus
About Nukkleus
Nukkleus Inc, a financial technology company, provides blockchain-enabled technology solutions worldwide. It focuses on providing software and technology solutions for retail foreign exchange trading industry. The company provides transactions platform for dealing and risk management services. It also offers cross-border payment and transactions solutions and blockchain-enabled financial services solutions to institutional investors. In addition, the company provides software, technology, customer sales and marketing, and risk management technology hardware and software solutions.
Read More
- Five stocks we like better than Nukkleus
- Running on Empty: 3 Energy Plays for Europe’s Deep Freeze
- 3 Healthcare Stocks for 3 Stages of Life
- Curaleaf Tries To Roll Up Aurora In a Hostile Cannabis Bid
- MarketBeat’s Most Downgraded Stocks in Q3: 2 Look Cheap, 1 Looks Risky
Receive News & Ratings for Nukkleus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nukkleus and related companies with MarketBeat.com's FREE daily email newsletter.
